Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells

Pancreatic ductal adenocarcinoma (PDAC) remains a particularly lethal disease that is resistant to targeted therapies. Tyrosine kinase inhibitors (TKIs), including erlotinib and gefitinib, which block the action of the human epidermal growth factor receptor type 1 receptor, provide small increases i...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Nimmi A., Abraham, Rita G., Dedi, Brixhilda, Krucher, Nancy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317693/
https://www.ncbi.nlm.nih.gov/pubmed/30535494
http://dx.doi.org/10.3892/ijo.2018.4658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317693/
https://www.ncbi.nlm.nih.gov/pubmed/30535494
http://dx.doi.org/10.3892/ijo.2018.4658

Ejemplares similares